Related Experiment Video
Updated: Nov 4, 2025
Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
Published on: May 16, 2019
Current Pharmacologic Strategies for Treatment of Intractable Epilepsy in Children
1Department of Pediatrics, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Insights
Epileptic encephalopathy (EE) involves severe pediatric seizures and developmental delays. This review explores molecular causes and treatments for common EEs, highlighting the need for new therapies.
Area of Science:
- Pediatric Neurology
- Neuroscience
- Molecular Biology
Background:
- Epileptic encephalopathy (EE) is a severe pediatric neurological disorder characterized by drug-resistant seizures and global developmental delays.
- The underlying neurobiological mechanisms of EEs remain poorly understood, limiting therapeutic interventions.
- Common pediatric EEs include Ohtahara syndrome, Dravet syndrome, and Lennox-Gastaut syndrome.
Purpose of the Study:
- To review the molecular mechanisms underlying common pediatric epileptic encephalopathies.
- To discuss the role of molecular dysregulation in excitation/inhibition imbalances in EEs.
- To examine current antiepileptic drug treatments and identify needs for future drug development.
Main Methods:
- Literature review of pediatric epileptic encephalopathies.
- Analysis of molecular mechanisms, focusing on excitation/inhibition imbalances.
- Discussion of voltage-gated ion channels, synaptic proteins, and ligand-gated ion channels in EE pathophysiology.
Main Results:
- Identified common pediatric EEs (Ohtahara, Dravet, Lennox-Gastaut syndromes) and their associated molecular targets.
- Detailed the role of specific molecular dysfunctions in excitation/inhibition imbalances.
- Highlighted the limited efficacy of current antiepileptic drugs for intractable EE seizures.
Conclusions:
- Understanding molecular mechanisms of EEs is crucial for developing targeted therapies.
- Further research into molecular pathways is essential for improving seizure control in intractable epilepsy.
- Novel therapeutic strategies are needed for pediatric patients with drug-resistant epileptic encephalopathies.
Abstract:
Epileptic encephalopathy (EE) is a devastating pediatric disease that features medically resistant seizures, which can contribute to global developmental delays. Despite technological advancements in genetics, the neurobiological mechanisms of EEs are not fully understood, leaving few therapeutic options for affected patients. In this review, we introduce the most common EEs in pediatrics (i.e., Ohtahara syndrome, Dravet syndrome, and Lennox-Gastaut syndrome) and their molecular mechanisms that cause excitation/inhibition imbalances. We then discuss some of the essential molecules that are frequently dysregulated in EEs. Specifically, we explore voltage-gated ion channels, synaptic transmission-related proteins, and ligand-gated ion channels in association with the pathophysiology of Ohtahara syndrome, Dravet syndrome, and Lennox-Gastaut syndrome. Finally, we review currently available antiepileptic drugs used to treat seizures in patients with EEs. Since these patients often fail to achieve seizure relief even with the combination therapy, further extensive research efforts to explore the involved molecular mechanisms will be required to develop new drugs for patients with intractable epilepsy.
More Related Videos
10:22Interictal High Frequency Oscillations Detected with Simultaneous Magnetoencephalography and Electroencephalography as Biomarker of Pediatric Epilepsy
Published on: December 6, 2016
09:57Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization
Published on: September 20, 2024
Related Concept Videos
01:14Antiepileptic Drugs: Glutamate Antagonists
01:08Antiepileptic Drugs: Sodium Channel Blockers
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
01:24Epilepsy and Seizures: Overview
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
01:17Antiepileptic Drugs: Calcium Channel Blockers
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...